Report Scope & Overview:

The Biobanking Market Size was valued at USD 48.65 billion in 2022, and is expected to reach USD 86.77 billion by 2030, and grow at a CAGR of 7.5% over the forecast period 2023-2030.

A biobank is a form of biorepository that holds biological samples for research purposes. Biobanks have become a valuable resource in medical research, supporting a wide range of modern studies such as genomics and customised medicine. Scientists can use biobanks to gain access to data from a large number of people. Materials from Biobanks and data derived from those samples are frequently used by several researchers for research purposes. Biobanks are collections of human biological materials such as plasma, pure DNA, blood, saliva, and other biospecimens that are stored, distributed, and collected in one location.

Biobanking Market

Biobanks assist in the storage of a patient's personal and medical information. Maintaining biobanks for preserving biological resources necessitates a suitable environment. These materials and data are used to diagnose diseases and determine their causes. Many disorders, for example, are linked to single-nucleotide polymorphism. The registration of each sample entering and exiting the systems are saved centrally, generally on a computer system that can be regularly backed up. Existing systems are compact, keeping approximately 41,000 samples in less than a quarter of the space required by a -81°C freezer. For the sake of security, copy tests are habitually kept in a different spot.



  • Biobanking advancements and the rising prevalence of saving newborns' cord blood stem cells

  • The demand for low-cost drug discovery and development is growing.

  • Supporting Regenerative Medicine Research with Public and Private Funding

  • Intensification of disease-related genomic research


  • Problems in Obtaining Biospecimen Samples

  • Automation's High Costs


  • Emerging Markets

  • Rising Interest in Cell Therapy Research and Development


  • Biobanks' Long-Term Viability


The coronavirus, also known as the Covid 19 pandemic, had a negative effect on the biobanking industry, as the growing numbers of Covid cases has raised concerns about the risks associated with storage, collection, and processing of human biospecimens and all biological materials, as larger transmission of viruses and other diseases would result during the pandemic period. Several biobanking firms that were still collecting human cell and tissue samples saw the implications when the samples for cancer treatment were discovered to be infected with SARS CoV-2 and had become a carrier of the lethal virus, which has become a threat to most biobanking organisations.

Be that as it may, then again, different advances have been taken and assets have been used to frame structures at low levels to gather tests of SARS Cov-2 from a huge base of populace and to control what is happening of the pandemic through the improvement of immunizations and to give an exploration base to all genomic investigates and advancement of medical care frameworks.

By Specimen type

Due to a growth in the incidence of hematological illnesses, a rise in demands for blood products for collecting specimens, and a rise in accidents, the blood products sector dominated the market in 2020 and is probably going to proceed with this pattern during the estimate time frame. Moreover, due to an increase in demand for regenerative medicines, an increase in the prevalence of cardiovascular and neurological illnesses, and a surge in the requirement for organ storage for transplant, the solid tissue segment is likely to develop significantly throughout the forecast period.

By Application type

According to the rise in the number of chronic diseases and breakthroughs in tissue regeneration, the research sector dominated the market in 2021 and is likely to do so throughout the forecast period. The therapeutic segment, on the other hand, is predicted to develop significantly over the projection period, owing to an increase in the frequency of chronic diseases and trauma crises, as well as an expansion in the occurrence of degenerative illnesses and a shortage of organs for transplantation.

By Type

Real biobanks and virtual biobanks have now been added to the worldwide market. In 2021, physical/real biobanks dominated the market, accounting for 80.4 percent of total revenue. These biobanks have a well-established network and so control a large portion of the revenue pie. The biobanks' new working model can be credited with rapid advancement in the realms of bioinformatics analysis and precision medicine. Tissue banks account for the greatest share of tissue banks in 2021, thanks to a significant collection of tissue samples collected over time from pathological labs, therapeutic trials, and research projects.

By Service

Biobanking & repository, lab processing, qualification/validation, cold chain logistics, and other services have all been sub-segmented into the global market. In 2021, the biobanking and repository services category dominated the market, accounting for around 38.00% of total revenue. This is due to the rising need for bio sample preservation in order to develop precision medicine and disease-specific research, as well as the increased market penetration of these services. The segment has benefited from the spread of biobanking services from university research to clinical enterprises and government efforts, as well as highly-connected and open-ended ventures.


Some of the major key players are as follows: Avantor, BioCision, Becton, Dickinson and Company (BD), Danaher Corporation, Hamilton Company, Merck KGaA, QIAGEN, Thermo Fisher Scientific, Inc., Tecan Trading AG., Taylor-Wharton.


By Specimen type

  • Solid Tissue

  • Nucleic Acid

  • Cell Lines

  • Blood Products

  • Others

By Type

  • Disease-oriented

  • Population

By Service

  • Qualification/ Validation

  • Cold Chain Logistics

  • Biobanking & Repository

  • Lab processing

  • Other Services

By Application type

  • Research

  • Therapeutic

By End User

  • Pharma & Biotech Companies

  • Academic Institutions

Biobanking Market


North America, Europe, Asia Pacific, and the Rest of the World are the regions that make up the global biobanking market. Over the projected period, North America is expected to dominate the Biobanking market, followed by Europe and Asia Pacific. In contrast, due to the expanding healthcare and diagnostics infrastructure across the region, Asia Pacific is predicted to develop at the fastest CAGR.


  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

Biobanking Market Report Scope:
Report Attributes Details
Market Size in 2022 US$ 48.65 Billion
Market Size by 2030 US$ 86.77 Billion
CAGR CAGR of 7.5% From 2023 to 2030
Base Year 2022
Forecast Period 2023-2030
Historical Data 2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Specimen type (Solid Tissue, Nucleic Acid, Cell Lines, Blood Products, Others)
• By Type (Disease-oriented, Population)
• By Service (Qualification/ Validation, Cold Chain Logistics, Biobanking & Repository, Lab processing, Other Services)
• By Application Type (Research, Therapeutic)
• By End User (Pharma & Biotech Companies, Academic Institutions)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Avantor, BioCision, Becton, Dickinson and Company (BD), Danaher Corporation, Hamilton Company, Merck KGaA, QIAGEN, Thermo Fisher Scientific, Inc., Tecan Trading AG., Taylor-Wharton.
DRIVERS • Biobanking advancements and the rising prevalence of saving newborns' cord blood stem cells
• The demand for low-cost drug discovery and development is growing.
• Supporting Regenerative Medicine Research with Public and Private Funding
OPPORTUNITIES • Problems in Obtaining Biospecimen Samples
• Automation's High Costs

Frequently Asked Questions

Top-down, bottom-up, Quantitative, Qualitative Research, Descriptive, Analytical, Applied, Fundamental Research.

Disease-oriented, and Population are the sub segments of by type.

Key drivers of the Pet Oral Care Products Market the demand for low-cost drug discovery and development is growing, and Supporting Regenerative Medicine Research with Public and Private Funding.

Segments of Biobanking market are By Specimen type, By Type, By Service, By Application type, and By End User.

Biobanking Market Size was valued at USD 45.262 billion in 2021 and expected to reach USD 75.092 billion by 2028, and grow at a CAGR of 7.5% over the forecast period 2022-2028.

Table of Contents


1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions


2. Research Methodology


3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges


4. Impact Analysis

4.1 COVID-19 Impact Analysis

4.2 Impact of Ukraine- Russia war

4.3 Impact of ongoing Recession

4.3.1 Introduction

4.3.2 Impact on major economies US Canada Germany France United Kingdom China Japan South Korea Rest of the World

5. Value Chain Analysis


6. Porter’s 5 forces model


7.  PEST Analysis


8. Biobanking Market Segmentation, By Specimen Type

8.1 Solid Tissue

8.2 Nucleic Acid

8.3 Cell Lines

8.4 Blood Products

8.5 Others


9. Biobanking Market Segmentation, By Type

9.1 Disease-oriented

9.2 Population


10. Biobanking Market Segmentation, By Service

10.1 Qualification/ Validation

10.2 Cold Chain Logistics

10.3 Biobanking & Repository

10.4 Lab processing

10.5 Other Services


11. Biobanking Market Segmentation, By Application Type

11.1 Research

11.2 Therapeutic


12. Biobanking Market Segmentation, By End User

12.1 Pharma & Biotech Companies

12.2 Academic Institutions


13. Regional Analysis

13.1 Introduction

13.2 North America

13.2.1 USA

13.2.2 Canada

13.2.3 Mexico

13.3 Europe

13.3.1 Germany

13.3.2 UK

13.3.3 France

13.3.4 Italy

13.3.5 Spain

13.3.6 The Netherlands

13.3.7 Rest of Europe

13.4 Asia-Pacific

13.4.1 Japan

13.4.2 South Korea

13.4.3 China

13.4.4 India

13.4.5 Australia

13.4.6 Rest of Asia-Pacific

13.5 The Middle East & Africa

13.5.1 Israel

13.5.2 UAE

13.5.3 South Africa

13.5.4 Rest

13.6 Latin America

13.6.1 Brazil

13.6.2 Argentina

13.6.3 Rest of Latin America


14 Company Profiles

14.1 Avantor

            14.1.1 Financial

14.1.2 Products/ Services Offered

14.1.3 SWOT Analysis

14.1.4 The SNS view

14.2 BioCision

14.3 Becton

14.4 Dickinson and Company (BD)

14.5 Danaher Corporation

14.6 Hamilton Company

14.7 Merck KGaA


14.9 Thermo Fisher Scientific, Inc.

14.10 Tecan Trading AG.


15 Competitive Landscape

15.1 Competitive Benchmark

15.2 Market Share analysis

15.3 Recent Developments


16 Conclusion


An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.


The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Share Page
Start a Conversation

Hi! Click one of our member below to chat on Phone